Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Jiangsu Hengrui Medicine Co., Ltd.
  6. Summary
    600276   CNE0000014W7

JIANGSU HENGRUI MEDICINE CO., LTD.

(600276)
  Report
End-of-day quote Shanghai Stock Exchange  -  2023-02-05
42.49 CNY   -0.72%
02/01Hengrui Pharmaceuticals Subsidiary Gets Regulatory Nod for Anti-Tumor Drug Trial
MT
01/16Chinese Shares Start Week Strong; Hengrui Medicine Jumps 10% as Regulator Approves New Chemo Drug
MT
01/16Jiangsu Hengrui Medicine Registers New Chemo Drug in China; Shares Rally 10%
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   End-of-day quote. End-of-day quote Shanghai Stock Exchange
01/31/2023 02/01/2023 02/02/2023 02/03/2023 02/06/2023 Date
42.21 42.64 43 42.8 42.49 Last
40917550 39641360 65348650 49801810 37917260 Volume
-2.40% +1.02% +0.84% -0.47% -0.72% Change
Estimated financial data (e)
Sales 2022 22 356 M 3 292 M 3 292 M
Net income 2022 4 247 M 625 M 625 M
Net cash position 2022 18 746 M 2 760 M 2 760 M
P/E ratio 2022 63,5x
Yield 2022 0,30%
Sales 2023 25 477 M 3 751 M 3 751 M
Net income 2023 4 955 M 730 M 730 M
Net cash position 2023 21 352 M 3 144 M 3 144 M
P/E ratio 2023 54,6x
Yield 2023 0,34%
Capitalization 271 B 40 074 M 39 901 M
EV / Sales 2022 11,3x
EV / Sales 2023 9,80x
Nbr of Employees 24 491
Free-Float 48,4%
More Financials
Company
Jiangsu Hengrui Medicine Co., Ltd. specializes in the research, development, manufacture and marketing of pharmaceutical products. The activity is organized primarily around 5 families of products: - anti-tumor drugs (No. 1 Chinese); - Anesthetic drugs; - contrast agents: used in medical imaging; - anti-inflammatory drugs; - drugs for the treatment of cardiovascular diseases. 
Sector
Pharmaceuticals
Calendar
04/20Earnings Release
More about the company
Ratings of Jiangsu Hengrui Medicine Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about JIANGSU HENGRUI MEDICINE CO., LTD.
02/01Hengrui Pharmaceuticals Subsidiary Gets Regulatory Nod for Anti-Tumor Drug Trial
MT
01/16Chinese Shares Start Week Strong; Hengrui Medicine Jumps 10% as Regulator Approves New ..
MT
01/16Jiangsu Hengrui Medicine Registers New Chemo Drug in China; Shares Rally 10%
MT
01/05Tranche Update on Jiangsu Hengrui Medicine Co., Ltd.'s Equity Buyback Plan announced on..
CI
2022Jiangsu Hengrui Pharma Gets Regulatory Nod For Anesthesia
MT
2022Hengrui Medicine Plans to Sell Shares to Fund Purchase of 51% Stake in Local Coal Miner
MT
2022Fire Rock CFO Resigns
MT
2022US FDA Approves Jiangsu Hengrui's MRI Contrast Agent
MT
2022Hengrui Pharmaceuticals' Anti-Cancer Drug Combination Put in Regulator's Priority Revie..
MT
2022Hengrui Pharmaceuticals Unit Gets Clinical Trial Approval for Malignant Tumor Treatment..
MT
2022COP27: Major food firms detail plans to eliminate deforestation by 2025
RE
2022Jiangsu Hengrui Medicine's Q3 Profit Slumps 32% as Revenue Slides 17%
MT
2022Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended S..
CI
2022Hengrui Pharmaceuticals' Lung Cancer Treatment Gets Breakthrough Therapy Designation in..
MT
2022Tranche Update on Jiangsu Hengrui Medicine Co., Ltd.'s Equity Buyback Plan announced on..
CI
More news
News in other languages on JIANGSU HENGRUI MEDICINE CO., LTD.
02/01Une filiale de Hengrui Pharmaceuticals obtient le feu vert réglementaire pour un essai ..
01/19La actualización de la Lista Nacional de Medicamentos Reembolsables de China cumple las..
01/16Les actions chinoises commencent la semaine en force ; Hengrui Medicine fait un bond de..
01/16Jiangsu Hengrui Medicine enregistre un nouveau médicament de chimiothérapie en Chine ; ..
2022Jiangsu Hengrui Pharma obtient le feu vert réglementaire pour l'anesthésie
More news
Analyst Recommendations on JIANGSU HENGRUI MEDICINE CO., LTD.
More recommendations
ETFs positioned on JIANGSU HENGRUI MEDICINE CO., LTD.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
KraneShares MSCI All China Health Care Inde...4.47%-6.47%China
KraneShares Emerging Market Healthcare Inde...3.69%-3.10%NC
Xtrackers Harvest FTSE China A-H 50 1D - USD2.06%-4.66%-China
Global X MSCI China Health Care ETF - USD1.82%-5.46%China
Pacer CSOP FTSE China A50 ETF - dis - USD1.32%-5.38%China
More ETFs positioned on JIANGSU HENGRUI MEDICINE CO., LTD.
Chart JIANGSU HENGRUI MEDICINE CO., LTD.
Duration : Period :
Jiangsu Hengrui Medicine Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JIANGSU HENGRUI MEDICINE CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Last Close Price 42,49 CNY
Average target price 50,89 CNY
Spread / Average Target 19,8%
EPS Revisions
Managers and Directors
Wei Dong Chairman-Supervisory Board
Piao Yang Sun Chairman
Yu Xu Compliance Manager
Shuang Xue Independent Director
Qian Wang Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JIANGSU HENGRUI MEDICINE CO., LTD.10.28%40 367
JOHNSON & JOHNSON-6.82%430 370
ELI LILLY AND COMPANY-7.31%322 186
NOVO NORDISK A/S0.37%309 611
ROCHE HOLDING AG-2.81%269 030
MERCK & CO., INC.-7.22%260 994